SBIR and STTR Success Story for
KeraMed Inc.

(Information Posted/Updated on 05/23/2010)

KeraMed Inc.
1270 Lawrence Station
Ste I
Sunnyvale, CA  94089

Contact:    Yichieh Shiuey
Phone:      4087520860
Web Site:  htttp://

Project Title:  Novel Keratoprosthesis Designs and Implantation Methods / A robotic device to faciliate corneal transplantation and other corneal surgeries
Related Award(s):  1R43EY017464-01, 1R43EY016617-01A1, 2R44EY016617-02A1
Technology Developed:
We have developed a new type of artificial cornea, called the KeraKlear, which can be used to treat cornea blindness without the need for donor corneal tissue. This artificial cornea can be implanted through a micro-incision of 3.5 mm using an automated robotic device developed by our company or with a femtosecond laser.

Key Words:  artificial cornea, cornea surgery, cornea blindness, robotic surgery.
Uses of Technology/Products/Service:
Our artificial cornea allows treatment of all kinds of cornea blindness without the need for donor tissue. This is an extremely important advantage because there is only enough donor tissue to treat 1% of the 10 million bilaterally cornea blind patients each year. Moreover, the combination of our artificial cornea and our automated robotic device allows the treatment of cornea blindness in the third world because the procedure is simple enough for even non-corneal specialist eye surgeons to perform the implantation.

The first two patients who received the implants had remarkably quick recoveries as compared to standard transplantation which typically requires about 12 months before good vision is obtained. The first patient was a 93 year old woman who had been blind for 30 years from an alkali injury and glaucoma. Before her surgery she could only see light, but after the surgery she was able to read the large letters on the eye chart and see the faces of her family. The second patient was even more remarkable. His vision improved from only being able to see hand motions before surgery to being able to read large print (20/80 vision) in one day.

Benefit to Company:
We will be eternally grateful to the SBIR program for giving us the seed funding to begin our artificial cornea project. Without SBIR funding we would never have been able to develop the prototypes that proved the feasibility of our technology.

How Product Was Commercialized:
The KeraKlear has received European CE Mark approval. We are currently organizing a U.S. FDA 510k clinical study to enable use of the product in the U.S.

Other Comments Related to Company's Success Story:
We wish to thank Dr. Jerry Wujek, National Eye Institute SBIR program director, Tina Jones, and Keturah Williams for their guidance and help in the the grant submission process.